Commitments and Contingencies (Details Narrative) - USD ($) |
12 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|
Aug. 05, 2020 |
Dec. 04, 2019 |
Jul. 25, 2019 |
Jun. 21, 2019 |
Apr. 02, 2019 |
Jan. 14, 2019 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
Value of shares issued for service | $ 10,802 | |||||||
Litigation settlement expense | 75,000 | |||||||
Neelima Varma and St.David's [Member] | ||||||||
Loss contingency, seeking description | On July 25, 2019, the Company was notified that on July 23, 2019, a complaint was filed by Neelima Varma, against the Company and St. David's Healthcare Partnership, L.P., LLP ("St. David's"), in the district court of Travis County, Texas, alleging, among other things, negligence gross negligence and strict product liability, breach of express warranty, breach of implied warranty and fraudulent misrepresentation and omission with respect to a medical device which the Company had sold through one of its distributors to St. David's. Mr. Varna was seeking aggregate monetary relief from the company and St. David's in excess of $1,000,000. | |||||||
St.David's [Member] | ||||||||
Loss contingency, seeking excess value | $ 1,000,000 | |||||||
Settlement Agreement [Member] | ||||||||
Loss contingency, damages sought, value | $ 1,551,562 | |||||||
Lump sum payment | $ 1,350,000 | |||||||
Settlement Agreement [Member] | Watts Action [Member] | ||||||||
Payment of attorney' fees | $ 200,000 | |||||||
Settlement Agreement [Member] | Watts and Chan Action [Member] | ||||||||
Payment of attorney' fees | $ 325,000 | |||||||
Settlement Agreement and General Release [Member] | ||||||||
Litigation settlement expense | 2,810,000 | |||||||
Settlement Agreement and General Release [Member] | ChubeWorkx [Member] | ||||||||
Litigation settlement amount paid | $ 300,000 | |||||||
Stock issued during the period | 500,000 | |||||||
Fair market value | $ 2,510,000 | |||||||
General and Administrative Expense [Member] | ||||||||
Administrative Expenses | $ 50,000 | $ 50,000 | ||||||
Advisor One [Member] | ||||||||
Value of shares issued for service | $ 25,000 | |||||||
Advisor Two [Member] | ||||||||
Value of shares issued for service | $ 25,000 |
X | ||||||||||
- Definition Loss contingency, seeking excess value. No definition available.
|
X | ||||||||||
- Definition Lump sum payment. No definition available.
|
X | ||||||||||
- Definition Payment of attorney' fees. No definition available.
|
X | ||||||||||
- Definition Amount awarded to other party in judgment or settlement of litigation. No definition available.
|
X | ||||||||||
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. No definition available.
|
X | ||||||||||
- Definition Describes the form and magnitude of the award the plaintiff seeks in the legal matter, which may include an unspecified amount of money. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. No definition available.
|
X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|